Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Prilenia Neurotherapeutics Ltd. has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are handled by 3 distinct examiners across 3 distinct art units. AGGARWAL, SAHIL CHANDER is the busiest examiner, with 1 pending action currently assigned.
The distribution shows that each of the 3 pending office actions is being reviewed by a different individual in a different specialized group. This lack of overlap across 3 distinct art units suggests that the company's pharmaceutical filings cover varied technical niches. Prosecution requires managing three separate examiner relationships simultaneously.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| JAVANMARD, SAHAR | 1 | 64.9% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18553758 | TREATMENT OF PRODROMAL HUNTINGTON DISEASE | JAVANMARD, SAHAR | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19391284 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE | AGGARWAL, SAHIL CHANDER | 1623 | §102§103DP | Non-Final OA | — | Pending | Nov 17, 2025 |
| 18553758 | TREATMENT OF PRODROMAL HUNTINGTON DISEASE | JAVANMARD, SAHAR | 1622 | §103Other | Non-Final OA | — | Pending | Oct 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrilenia Neurotherapeutics Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sahil Chander Aggarwal has the most, with 1 of Prilenia Neurotherapeutics Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
